Compare Stocks: BTAI, ALZN, MTVA, and XCUR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.94 +2.6%	$1.52	$0.84 ▼ $2.68	$9.12M	0.23	111,850 shs	206,602 shs
BTAI BioXcel Therapeutics	$0.07 +0.3%	$0.61	$0.07 ▼ $4.29	$2.32M	0.19	17.36 million shs	42.29 million shs
MTVA MetaVia	$1.67 -3.5%	$1.59	$0.97 ▼ $14.85	$8.93M	0.94	93,821 shs	45,245 shs
XCUR Exicure	$1.26 +2.4%	$1.44	$1.05 ▼ $9.48	$8.05M	3.63	36,998 shs	32,063 shs

10 Best Stocks to Own - Fall 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Fall 2026, despite the economic uncertainty rattling markets right now. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	+2.65%	+10.86%	+24.36%	+41.61%	-19.17%
BTAI BioXcel Therapeutics	0.00%	0.00%	-90.78%	-94.12%	-97.52%
MTVA MetaVia	-3.47%	+3.09%	+14.38%	+8.44%	-85.40%
XCUR Exicure	+2.44%	-8.03%	+9.57%	-53.85%	-67.19%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALZN Alzamend Neuro	$1.94 +2.6%	$1.52	$0.84 ▼ $2.68	$9.12M	0.23	111,850 shs	206,602 shs
BTAI BioXcel Therapeutics	$0.07 +0.3%	$0.61	$0.07 ▼ $4.29	$2.32M	0.19	17.36 million shs	42.29 million shs
MTVA MetaVia	$1.67 -3.5%	$1.59	$0.97 ▼ $14.85	$8.93M	0.94	93,821 shs	45,245 shs
XCUR Exicure	$1.26 +2.4%	$1.44	$1.05 ▼ $9.48	$8.05M	3.63	36,998 shs	32,063 shs

10 Best Stocks to Own - Fall 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALZN Alzamend Neuro	+2.65%	+10.86%	+24.36%	+41.61%	-19.17%
BTAI BioXcel Therapeutics	0.00%	0.00%	-90.78%	-94.12%	-97.52%
MTVA MetaVia	-3.47%	+3.09%	+14.38%	+8.44%	-85.40%
XCUR Exicure	+2.44%	-8.03%	+9.57%	-53.85%	-67.19%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALZN Alzamend Neuro	2.00	Hold	$28.00	1,343.30% Upside
BTAI BioXcel Therapeutics	2.25	Hold	$11.00	14,744.80% Upside
MTVA MetaVia	2.00	Hold	$20.00	1,097.60% Upside
XCUR Exicure	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest BTAI, ALZN, MTVA, and XCUR Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/8/2026	XCUR Exicure	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/31/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
8/17/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
8/3/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)
7/21/2026	MTVA MetaVia	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/20/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (E+) ➝ Sell (E)
7/17/2026	BTAI BioXcel Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/10/2026	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
6/29/2026	ALZN Alzamend Neuro	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E) ➝ Sell (E+)

(Data available from 9/21/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	$0.19 per share	N/A
BTAI BioXcel Therapeutics	$640K	3.63	N/A	N/A	($4.37) per share	-0.02
MTVA MetaVia	N/A	N/A	N/A	N/A	$2.31 per share	N/A
XCUR Exicure	$500K	16.51	N/A	N/A	$0.62 per share	2.03

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALZN Alzamend Neuro	-$8.77M	-$2.30	N/A	N/A	N/A	N/A	-277.88%	-184.20%	12/8/2026 (Estimated)
BTAI BioXcel Therapeutics	-$69.90M	-$3.79	N/A	N/A	N/A	-9,549.87%	N/A	-185.82%	11/11/2026 (Estimated)
MTVA MetaVia	-$12.97M	-$3.23	N/A	N/A	N/A	N/A	-209.67%	-107.91%	11/5/2026 (Estimated)
XCUR Exicure	-$4.95M	-$1.32	N/A	N/A	N/A	N/A	-237.91%	-61.98%	11/12/2026 (Estimated)

Latest BTAI, ALZN, MTVA, and XCUR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
9/10/2026	Q1 2027	ALZN Alzamend Neuro	-$0.56	-$0.68	-$0.12	-$0.68	N/A	N/A
8/14/2026	Q2 2026	XCUR Exicure	-$18.60	-$0.18	+$18.42	-$0.18	$1.64 million	N/A
8/13/2026	Q2 2026	BTAI BioXcel Therapeutics	-$0.44	-$0.49	-$0.05	-$0.49	$0.49 million	$0.18 million
8/6/2026	Q2 2026	MTVA MetaVia	-$0.82	-$0.90	-$0.08	-$0.90	N/A	N/A
7/22/2026	Q4 2026	ALZN Alzamend Neuro	-$0.67	-$0.74	-$0.07	-$0.74	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALZN Alzamend Neuro	N/A	N/A	N/A	N/A	N/A
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A
XCUR Exicure	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALZN Alzamend Neuro	N/A	3.01	3.01
BTAI BioXcel Therapeutics	N/A	0.21	0.21
MTVA MetaVia	N/A	2.06	2.06
XCUR Exicure	N/A	0.56	0.56

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALZN Alzamend Neuro	49.61%
BTAI BioXcel Therapeutics	30.68%
MTVA MetaVia	1.37%
XCUR Exicure	42.82%

Insider Ownership

Company	Insider Ownership
ALZN Alzamend Neuro	1.39%
BTAI BioXcel Therapeutics	3.70%
MTVA MetaVia	0.60%
XCUR Exicure	52.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALZN Alzamend Neuro	6	4.83 million	4.76 million	No Data
BTAI BioXcel Therapeutics	90	31.31 million	30.15 million	No Data
MTVA MetaVia	8	5.16 million	5.13 million	N/A
XCUR Exicure	50	6.55 million	3.09 million	Not Optionable

BTAI, ALZN, MTVA, and XCUR Headlines

Recent News About These Companies

Exicure Granted Extension By Nasdaq To Regain Compliance By Dec. '26

September 16, 2026 | rttnews.com

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders’ Equity Requirement

September 16, 2026 | finance.yahoo.com

Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement

September 16, 2026 | globenewswire.com

Exicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics

August 3, 2026 | quiverquant.comQ

Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance

August 3, 2026 | globenewswire.com

Exicure Inc (NASDAQ: XCUR) - Share Price and Research

July 15, 2026 | intelligentinvestor.com.auI

Exicure Reaches Preliminary Settlement in Derivative Lawsuits

July 9, 2026 | theglobeandmail.com

Exicure Announces Board and Committee Changes

June 30, 2026 | globenewswire.com

Exicure, Inc.: Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 11, 2026 | finanznachrichten.de

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

June 10, 2026 | markets.businessinsider.com

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

June 10, 2026 | globenewswire.com

Exicure Regains Nasdaq Compliance After Late Quarterly Filing

June 1, 2026 | tipranks.com

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

June 1, 2026 | globenewswire.com

Exicure delays quarterly filing, trims quarterly loss

May 15, 2026 | tipranks.com

Exicure, Inc. and Adbiotech Co., Ltd. Announce Co-Development Agreement for Burixafor Combination Therapies

April 22, 2026 | quiverquant.comQ

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

April 22, 2026 | globenewswire.com

Exicure Inc.

April 13, 2026 | barrons.com

Exicure Strengthens Leadership With New COO and Director

April 10, 2026 | tipranks.com

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

April 2, 2026 | globenewswire.com

Exicure, Inc. Reports 2025 Financial Results and Announces Need for Additional Financing

March 25, 2026 | quiverquant.comQ

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI, ALZN, MTVA, and XCUR Company Descriptions

Alzamend Neuro NASDAQ:ALZN

$1.94 +0.05 (+2.65%)

As of 09/21/2026 04:00 PM Eastern

Alzamend Neuro, Inc., an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.

BioXcel Therapeutics NASDAQ:BTAI

$0.07 +0.00 (+0.27%)

As of 09/4/2026

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

MetaVia NASDAQ:MTVA

$1.67 -0.06 (-3.47%)

As of 09/21/2026 04:00 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

Exicure NASDAQ:XCUR

$1.26 +0.03 (+2.44%)

As of 09/21/2026 04:00 PM Eastern

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BTAI, ALZN, MTVA, and XCUR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BTAI, ALZN, MTVA, and XCUR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BTAI, ALZN, MTVA, and XCUR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI, ALZN, MTVA, and XCUR Company Descriptions

Alzamend Neuro NASDAQ:ALZN

BioXcel Therapeutics NASDAQ:BTAI

MetaVia NASDAQ:MTVA

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BTAI, ALZN, MTVA, and XCUR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BTAI, ALZN, MTVA, and XCUR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BTAI, ALZN, MTVA, and XCUR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

BTAI, ALZN, MTVA, and XCUR Company Descriptions

Alzamend Neuro NASDAQ:ALZN

BioXcel Therapeutics NASDAQ:BTAI

MetaVia NASDAQ:MTVA

Exicure NASDAQ:XCUR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools